Author:
Clemons Julia,Gao Dexiang,Naam Mary,Breaker Kathryn,Garfield David,Flaig Thomas W.
Reference40 articles.
1. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004
2. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003
3. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer;Wilhelm;Nat Rev Drug Discov,2006
4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
5. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献